- Home
- TFPM vs EWTX Comparison
TFPM vs EWTX Comparison
Compare TFPM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFPM
- EWTX
- Stock Information
- Founded
- TFPM 2016
- EWTX 2017
- Country
- TFPM Canada
- EWTX United States
- Employees
- TFPM N/A
- EWTX N/A
- Industry
- TFPM Precious Metals
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TFPM Industrials
- EWTX Health Care
- Exchange
- TFPM Nasdaq
- EWTX Nasdaq
- Market Cap
- TFPM 3.3B
- EWTX 2.7B
- IPO Year
- TFPM N/A
- EWTX 2021
- Fundamental
- Price
- TFPM $15.39
- EWTX $30.78
- Analyst Decision
- TFPM Strong Buy
- EWTX Buy
- Analyst Count
- TFPM 4
- EWTX 6
- Target Price
- TFPM $20.50
- EWTX $44.83
- AVG Volume (30 Days)
- TFPM 321.6K
- EWTX 896.5K
- Earning Date
- TFPM 01-01-0001
- EWTX 02-20-2025
- Dividend Yield
- TFPM 1.45%
- EWTX N/A
- EPS Growth
- TFPM N/A
- EWTX N/A
- EPS
- TFPM N/A
- EWTX N/A
- Revenue
- TFPM $246,517,000.00
- EWTX N/A
- Revenue This Year
- TFPM $33.62
- EWTX N/A
- Revenue Next Year
- TFPM $11.43
- EWTX N/A
- P/E Ratio
- TFPM N/A
- EWTX N/A
- Revenue Growth
- TFPM 25.66
- EWTX N/A
- 52 Week Low
- TFPM $11.75
- EWTX $9.00
- 52 Week High
- TFPM $18.88
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- TFPM 34.49
- EWTX 48.57
- Support Level
- TFPM $15.81
- EWTX $29.39
- Resistance Level
- TFPM $17.01
- EWTX $35.50
- Average True Range (ATR)
- TFPM 0.40
- EWTX 2.42
- MACD
- TFPM -0.12
- EWTX 0.02
- Stochastic Oscillator
- TFPM 11.47
- EWTX 44.47
About TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a precious-metals-focused streaming and royalty company. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, and the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.